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Fluorescence in situ hybridization analysis of the
hTERC region in acute myeloid leukemia patients
Akut myeloid lösemi olgularında floresan in situ hibridizasyon
yöntemi ile hTERC bölgesinin analizi
Özge Özer, Tuğçe Bulakbaşı Balcı, Zerrin Yılmaz, Feride İffet Şahin
Department of Medical Genetics, Faculty of Medicine, Başkent University, Ankara, Turkey

Abstract
Objective: The telomerase RNA component (hTERC) gene is located at 3q26. Increased hTERC gene
expression has been frequently observed and amplification was shown using fluorescence in situ
hybridization (FISH) in different cancers. The aim of this study was to determine whether hTERC
gene amplification is detectable by FISH in acute myeloid leukemia (AML) cells.
Material and Methods: FISH and karyotype results at the time of diagnosis of 23 adult AML patients
were retrospectively evaluated. Additionally, fixed cells were hybridized with an hTERC region-specific FISH probe to determine gene amplification.
Results: Ten of the 23 patients had a normal karyotype and 6 had an abnormal karyotype. hTERC
region amplification was not observed in any of the patients.
Conclusion: Although it was reported that hTERC gene amplification may partially contribute to
increased telomerase expression and activity in leukemic cells, it is not possible to make such a conclusion based on the results of the this study, as hTERC amplification was not observed in the study
group. This suggests that increased telomerase activity via gene amplification in the development of
AML may not be as important a factor as it is in solid tumors. (Turk J Hematol 2011; 28: 103-6)
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Özet
Amaç: Telomeraz RNA komponenti (hTERC) geni 3q26 bölgesinde yer alır. Çeşitli kanserlerde artmış
hTERC gen anlatımı sıklıkla saptanmış ve FISH yöntemi ile gen amplifikasyonu gösterilmiştir. Bu
çalışmanın amacı akut miyeloid lösemi (AML) hücrelerinde hTERC gen amplifikasyonunun FISH
yöntemi ile saptanabilirliğinin araştırılmasıdır.
Yöntem ve Gereçler: Bu çalışmada 23 yeni tanı erişkin AML olgusunun FISH ve karyotip sonuçları
geriye dönük olarak değerlendirildi. Ayrıca gen amplifikasyonunu değerlendirebilmek için tespit edilmiş hücreler hTERC bölgesine özgül FISH probu ile melezlendi.
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Bulgular: Çalışma kapsamına alınan 23 hastanın 10’unda normal karyotip; 6 hastada anormal karyotip bulundu. Hastaların hiçbirinde hTERC bölgesinde gen amplifikasyonu saptanamadı.
Tartışma: Hasta grubumuzda hTERC amplifikasyonu bulmadık. Bu nedenle, hTERC gen amplifikasyonunun lösemik hücrelerde telomeraz anlatımı ve aktivitesini arttırmada kısmen etkili olduğunun
bildirilmesine karşın, çalışmamızın sonuçları ile benzer bir sonuca ulaşmak mümkün olmamıştır. Bu
sonuç, AML gelişiminde gen amplifikasyonu yoluyla telomeraz aktivite artışının, solid tümörlerde
olduğu kadar önemli bir faktör olmadığı görüşünü destekler niteliktedir. (Turk J Hematol 2011; 28: 103-6)
Anahtar kelimeler: AML, hTERC, FISH
Geliş tarihi: 11 Şubat 2010		

Kabul tarihi: 6 Eylül 2010

Introduction
Acute myeloid leukemia (AML) originates from
myeloid cells. The disease is characterized by rapid
proliferation of abnormal cells, which accumulate
in the bone marrow and interfere with the production of normal blood cells. AML is the most common form of acute leukemia in adults and its incidence increases with age [1]. Morphological, cytochemical, immunophenotypic, cytogenetic, and
molecular features of the blasts are important factors in the classification of AML patients [2].
Telomeres, located at the ends of chromosomes,
determine the replication capacity of cells. They
shorten during each cell division and it is generally
thought that telomere length serves as a clock for
cells. Telomerase is a ribonucleoprotein complex,
consisting of human transcriptase reverse transcriptase (hTERT), proteins (hTP1), and RNA template
for telomeric DNA synthesis (hTERC) [3]; this complex synthesizes telomeres and stabilizes their
length. Mutations in any of these components may
result in a rare bone marrow failure syndrome
known as dyskeratosis congenita [4].
Telomerase activity was reported to be low in
normal human somatic cells [3]. Proliferating cells
become senescent when telomeres are short and
when there is no telomerase activity. Cancer cells
are known to overcome this senescence pathway
and become immortalized. Immortalization is
almost always accompanied by expression of
telomerase, which is most likely necessary for the
continued growth of cancer cells. Telomerase is
activated in most malignant tumours, but is usually
inactive in normal somatic cells [3]. Despite the
questionable role of telomerase reactivation in cell
immortalization and carcinogenesis, telomerase
may serve as a diagnostic marker for tumor development [5]. Several studies have shown that telomerase activity can be used to differentiate malignant

from normal tissue in various organs; however, the
majority of reports are devoted either to telomerase
activity or expression [6]. The present study aimed
to determine the presence of amplification of the
hTERC component of the telomerase complex in
cultured bone marrow cells obtained from AML
patients.

Materials and Methods
The study included bone marrow samples taken
at the time of diagnosis from 23 AML adult patients
between 2006 and 2008 that analyzed in our cytogenetics laboratory. Conventional cytogenetic analysis
and FISH results for each patient were evaluated retrospectively, and additional hybridization with the
hTERC (3q26)/ 3q11 probe (Kreatech, The
Netherlands) was performed to determine hTERC
gene amplification. Slides were dehydrated in 70%,
85%, and 90% alcohol series, consecutively, and
dried at room temperature. Denaturation and hybridization were carried out in a HyBrite denaturation/
hybridization system for FISH (Vysis, UK). The probe
was denatured at 75°C for 5 min. Hybridization was
carried out at 37°C for 14-16 h. After hybridization, the
slides were washed in first post hybridization wash
buffer at 73°C for 2 min, and then in second post
hybridization wash buffer at room temperature for 1
min and counterstained with DAPI.
Signals were quantified in ≥200 cells for both
hTERC gene and 3q11 signals under oil immersion
at 1000× magnification using the recommended
filters. Results are expressed as the ratio of hTERC
signal (orange) to 3q11 signal (green). The expected ratio is 1:1; which indicates there is no gene
amplification and when the ratio of signals is ≥2:1,
it indicates hTERC gene amplification (Figure 1).
Our samples were chosen from archive material
consisting of patient samples who approved material useage after diagnostic procedures.
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Results
Among the 23 patients, 14 (60.9%) were male
and 9 (39.1%) female; median age was 49 years
(range: 15-76 years). Conventional cytogenetic and
routine FISH results are given in the Table 1.
Cytogenetic analysis was not possible in 7 patients
due to culture failure or because we did not find
suitable metaphases for chromosome analysis
(shown in the Table as N/A). In all, 10 of the 23
patients had a normal karyotype and 6 had an
abnormal karyotype. The observed abnormalities
included trisomy 8, t(1;3), der(7), t(15;17), del(5),
and inv(16). We did not observed any complex
karyotypes and the above-mentioned cytogenetic
defects were the only abnormality in each patient.
Routine FISH analysis showed that 5 patients had
t(15;17), 2 patients had t(8;21), 1 patient had triple
signal for the 8q22 region, 1 patient had a deletion
in the 5q31 region, and 1 patient had inv(16).
According to FISH analysis, none of the patients had
hTERC gene amplification.

Discussion
Normal human cells have low levels of telomerase expression; however, when telomere length
reaches a critical point abnormal activation of
telomerase can lead to immortalization and uncontrolled proliferation. This process is associated with
the development of many leukemias and lymphomas [8]. More than 80% of various cancers have
increased telomerase activity, and it has been
reported that amplification of the telomerase gene
might play a role in telomerase reactivation, which

Figure 1. Normal AML cells for hTERC gene amplification analysis
using FISH. The specific molecular probe for hTERC was labeled
with rhodamine (Spectrum Orange) and the 3q11 reference probe
was labeled with fluorescein (Spectrum Green)
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leads to cell immortalization and seems to be a
common event in carcinogenesis [9].
It has been reported that increased hTERT and/or
hTERC gene expression may be an important mechanism involved in upregulated telomerase activity.
Accordingly, investigation of hTERT and/or hTERC
amplification might be useful in the diagnosis and
follow-up of cancer patients [10]. In the present
study we only examined amplification of the hTERC
component, as it is known that hTERC gene amplification alone can result in increased telomerase
activity [10]. Further investigation of hTERT amplification may be useful for elucidating the interactions
of these genes in the progression of AML.
hTERC gene expression can be affected by and
regulated by various processes inside cells; namely,
gene amplification, transcriptional regulation, and
epigenetic modification [11]. It was suggested that
the high-level of expression and activity of telomerase observed in acute leukemia cells might be due
to hTERC gene amplification, which is localized at
3q26.3. FISH is a useful method for observing gene
amplification and was used in the present study to
determine hTERC gene amplification. Previous
studies have reported that amplification of hTERT
and hTERC genes in acute leukemia cells exhibit a
variable number of copies-as many as 12-based on
FISH analysis [12].
One study that included patients with different
types of leukemia subgroups reported that amplification of hTERC and hTERT genes was associated
with increased telomerase activity and expression
in leukemia cells [12]. Hematologic malignancies
differ from other cancers, as they do not originate
from cells with low-level telomerase activity.
Serakinci et al. reported that there was no amplification of the hTERT region in patients with monosomy 7 and no deletion at 7q31 [13]. In the present
study 1 patient had a derivative chromosome 7
(patient No. 10), which we think originated from a
translocation with an undefined chromosome. The
fact that we did not observe amplification of the
hTERC region in this patient supports the notion that
this amplification may not be a characteristic of leukemia cells with an abnormality in chromosome 7.
Nonetheless, the unknown chromosomal component of the translocation and the putative effector
genes on the derivative chromosome 7 should not
be overlooked.
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Table 1. The patients, and their conventional cytogenetic and FISH results
Patient Sex
Number
1

E

Age
76

Karyotype

FISH panel

N/A

Normal

2
E
15 47,XY,+8
				

8q22 triple
signal

3

E

24

46,XY,t(1;3) (p36.3;q21) Normal

4

K

64

N/A

Normal

5

E

27

Normal

Normal

6

K

28

N/A

t(15;17) +

7

K

34

N/A

t(15;17) +

8

K

50

Normal

t(15;17) +

9

E

49

Normal

Normal

10
E
47
			

46,XY,der(7)t(7;?)
t(8;21) +
(q32;?),t(8;21)(q22;q22)

11

E

33

46,XY,t(15;17)(q22;q21) t(15;17) +

12

E

55

N/A

Normal

13

E

52

N/A

t(8;21) +

14
E
37
			

46,XY,del(5)(q31)
[16]/46,XY[2]

Deletion 5q31

15

Normal

Normal

16
E
75
			

46XY,inv(16) (p13q22 )
[4]/46,XY[1]

inv(16) +

17

E

27

Normal

Normal

18

E

46

N/A

Normal

19

E

53

Normal

Normal

20

K

39

Normal

Normal

21

K

57

Normal

Normal

22

K

58

Normal

t(15;17) +

23

K

65

Normal

Normal

K

50

Given the genetic heterogeneity of AML, investigation of hTERC gene amplification and frequent
genetic changes could further delineate the tumor
biology and might be useful for determining the
prognostic factors in AML. In the present study
hTERC gene amplification in the bone marrow
samples was not observed, based on FISH analysis.
Given the limited number of cases included, it is not
possible to definitively conclude that hTERC gene
amplification has any impact on the clinical course
of AML or that its amplification based on FISH could
be used as a diagnostic marker; however, the present results are in agreement with those of previous
studies that have suggested that increased telomerase activity due to telomerase gene amplification
may not be as influential in leukemias as in solid

tumors [13]. Additional research (with larger
patients groups) on the expression of the hTERC
gene and other components of the telomerase
complex is warranted.
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